Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4-RD Results support the continued development of obexelimab for the treatment of IgG4-RD and potentially other
API integration connects SimpleNexus, an nCino Company, mobile-first homeownership solution with MortgagebotLOS to simplify U.S. home lending LEHI, Utah, Aug. 01, 2023 (GLOBE NEWSWIRE) — SimpleNexus (https://simplenexus.com/), an nCino (NASDAQ: NCNO) company and developer of
Bedford, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) — Conagen, the bioplatform innovator and biomanufacturer, and Sumitomo Chemical, Japan’s leading chemical company, have announced to jointly develop p-hydroxystyrene (HS) and its polymer, poly p-hydroxystyrene (PHS), using
Herzliya, Israel and Amsterdam, Netherlands, August 1, 2023 – Playtika Holding Corp. (NASDAQ: PLTK), a mobile games pioneer and interactive entertainment leader, and Azerion Group N.V. (EURONEXT: AZRN) one of Europe’s largest digital advertising and
FLUED x HubSpot TOKYO, July 31, 2023 (GLOBE NEWSWIRE) — FLUED Inc. (“FLUED”) announced that it has reached the platinum tier of HubSpot’s Solutions Partner Program, joining just six other Platinum-tiered partners in Japan, which